Detailed price information for Profound Medical Corp (PRN-T) from The Globe and Mail including charting and trades.

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

The EAU 2026 CAPTAIN study presentation will be given by Laurence Klotz, CM, MD, FRCSC, an esteemed urologist, a professor of surgery at the University of Toronto, the Sunnybrook Chair of Prostate ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, ...

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

Q4 2025 Management View Arun Menawat, Chairman & CEO, emphasized the completion of recruitment for CAPTAIN, the first multicenter, randomized, controlled trial comparing a new technology to robotic ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement ...

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private ...